The Diagnosis Value of Promoter Methylation of UCHL1 in the Serum for Progression of Gastric Cancer

Table 5

Clinical characteristics of patients correlate with overall survival by Cox proportional hazard regression analysis.

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI	value	HR	95% CI	value
Age (<60 y, ≥60 y)	3.821	1.104–13.224	0.034	0.990	0.222–4.412	0.990
Gender (female, male)	0.966	0.375–2.493	0.943
Alcohol consumption (no, yes)	1.774	0.665–4.732	0.252
H. pylori infection (no, yes)	2.076	0.740–5.826	0.165
Histological type (intestinal, diffuse)	0.435	0.126–1.506	0.189
Differential (good/moderate, poor)	3.422	1.321–8.861	0.011	2.223	0.865–6.232	0.095
TNM stage (I + II, III + IV)	16.434	3.760–51.834	0.000	10.799	2.013–37.938	0.005
Lymph node metastasis (N0, N1–3)	1.988	0.653–6.054	0.226
Tumor size (<3 cm, ≥3 cm)	1.198	0.450–3.194	0.717
FLNC methylation (no, yes)	3.798	0.416–26.502	0.132
THBS1 methylation (no, yes)	3.262	0.943–11.285	0.062
UCHL1 methylation (no, yes)	6.694	1.536–19.172	0.011	3.688	0.769–14.677	0.103
DLEC1 methylation (no, yes)	4.162	0.553–31.308	0.166

HR, hazard ratio; CI, confidence interval; values < 0.05 are presented in bold.